Topical Steroids for UTI Prevention in Infants
(STRUMI-T Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether a steroid cream (Betamethasone Valerate) can prevent urinary tract infections (UTIs) in uncircumcised male infants. Infants in the study will receive either the steroid cream or a placebo cream that looks identical but contains no active ingredients. The cream is applied twice a week for four weeks, followed by check-ups to assess its effectiveness in preventing UTIs. Uncircumcised male infants under six months old who have experienced a doctor-confirmed UTI with symptoms like fever may qualify for this study. As a Phase 4 trial, this research aims to understand how the already FDA-approved and effective treatment benefits a broader patient population.
Do I have to stop my baby's current medications for this trial?
The trial information does not specify whether you need to stop your baby's current medications. It's best to discuss this with the research team.
What is the safety track record for Betamethasone Valerate?
Past research has used Betamethasone Valerate, a steroid cream, to treat skin issues like redness and swelling. Studies have shown that it is generally safe when used as directed, with serious side effects being rare. Most side effects involve mild skin irritation, such as itching or redness at the application site, and these usually resolve on their own.
The FDA has already approved the treatment for other uses, indicating its general safety. This trial is in a later stage, suggesting strong evidence of the treatment's safety for people. However, following all guidelines provided during the trial is important to minimize potential risks.12345Why are researchers enthusiastic about this study treatment?
Most treatments for urinary tract infections (UTIs) in infants involve antibiotics, which can lead to resistance and other side effects. Betamethasone Valerate, the treatment under study, is unique because it uses a topical steroid cream that can be applied directly to the skin, potentially reducing the risk of UTIs without systemic exposure. Researchers are excited about this treatment because it offers a non-invasive alternative that could help prevent UTIs while minimizing the use of antibiotics. This approach could be a game-changer in managing infant UTIs, offering a targeted preventative measure with fewer side effects.
What evidence suggests that this treatment might be an effective treatment for urinary tract infections?
Research has shown that using a steroid cream, such as Betamethasone Valerate, can reduce the risk of repeated urinary tract infections (UTIs) in uncircumcised baby boys. One study found that applying this cream to treat phimosis—a condition where the foreskin is too tight to retract—resulted in fewer UTIs in these infants. This trial will compare the effects of Betamethasone Valerate cream with a placebo cream to evaluate its effectiveness in preventing UTIs. The evidence supports the potential of steroid cream as a preventive measure for UTIs in this group.678910
Are You a Good Fit for This Trial?
This trial is for uncircumcised male infants under 6 months old who have had their first urinary tract infection confirmed by a doctor and lab tests. Infants must not have certain penile abnormalities, allergies to steroid creams, or prior use of topical steroids.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either the steroid cream or placebo cream applied twice a week for four weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment, including measuring urinary tract infections and parent perceptions
What Are the Treatments Tested in This Trial?
Interventions
- Betamethasone Valerate
Trial Overview
The study compares a steroid cream (betamethasone valerate 0.1%) with a placebo cream applied twice weekly for four weeks to see if the steroid can help prevent more urinary tract infections in these infants.
How Is the Trial Designed?
2
Treatment groups
Active Control
Placebo Group
Find a Clinic Near You
Who Is Running the Clinical Trial?
Baylor College of Medicine
Lead Sponsor
Seattle Children's Hospital
Collaborator
Citations
Topical Steroids to Prevent Recurrent Urinary Tract ...
Male infants, who are enrolled in this study, would receive either the steroid cream or a placebo cream (a look alike cream without steroids).
2.
researchgate.net
researchgate.net/publication/396358105_Phimosis_Treatment_and_Recurrent_Urinary_Tract_Infection_Risk_in_InfantsPhimosis Treatment and Recurrent Urinary Tract Infection ...
Conclusion: The use of steroid cream for physiologic phimosis is associated with a decreased risk of recurrent UTIs in uncircumcised male ...
The use of steroid cream for physiologic phimosis in male ...
The use of steroid cream for physiologic phimosis is associated with a decreased risk of recurrent UTIs in uncircumcised male in- fants with a ...
The Use of Steroid Cream for Physiologic Phimosis in Male ...
Conclusion: The use of steroid cream for physiologic phimosis is associated with a decreased risk of recurrent UTIs in uncircumcised male infants with a normal ...
5.
cidrap.umn.edu
cidrap.umn.edu/antimicrobial-stewardship/trial-finds-limited-benefit-continuous-antibiotic-prevention-infantTrial finds limited benefit from continuous antibiotic ...
In the intention-to-treat analysis, 31 infants (21.2%) in the prophylaxis group developed a first UTI, compared with 52 (35.6%) in the untreated ...
Review of non-antibiotic treatment and prevention of recurrent ...
The lifetime prevalence of at least one symptomatic UTI in women is estimated to exceed 50%, with 20%–40% experiencing recurrent UTIs (rUTIs).
208079Orig1s000 - accessdata.fda.gov
Parallel Group Study of the Efficacy and Safety of Betamethasone Dipropionate ... and moderate urinary tract infection on Day 26. None were considered related ...
Prevention of Recurrent Urinary Tract Infection in Women
Results showed a significant 51.9% reduction in UTI frequency in the year following prescription, with 55.3% of patients experiencing ≤1 UTI and ...
Betamethasone dipropionate Medicare coverage
Betamethasone is a potent (strong) medication used to relieve the inflammation (redness, swelling, warmth, pain) and itching from different skin conditions.
Recurrent Urinary Tract Infections - StatPearls - NCBI Bookshelf
The oral vaccine, MV140, has shown good efficacy in preventing recurrent UTIs in several studies with safety data and minimal adverse effects. A preliminary ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.